Abstract
Background Acute myeloid leukemia (AML) can develop secondary to drug treatment. This phenomenon has been placed under the title “Therapy Related Acute Myeloid Leukemias and Myelodysplastic Syndromes” in the WHO classification of AML. Cyclophosphamide, which is used in various malignancies and rheumatological diseases, is an alkylating agent that plays a significant role in therapy related AML. Case description A patient treated with cyclophosphamide due to vasculitis, subsequently developed AML months after treatment. Conclusion Cyclophosphamide related AML is seen, in most cases, many years after exposure to the drug. The significance of this report lies in the fact that, to our knowledge, this is the most rapidly arising case of cyclophosphamide related AML.
References
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.
Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62:9–21.
Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica. 1999;84:937–45.
de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135–64.
Langford CA. Complications of cyclophosphamide therapy. Eur Arch Otorhinolaryngol. 1997;254:65–72.
National Institutes of Health, National Cancer Institute. Adult Acute Myeloid Leukemia Treatment (PDQ®), Alkylating agent-related acute myeloid leukemia and myelodysplastic syndromes (updated 28 March 2014; cited 23 Dec 2014) (about 12 screens). http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional/page2#Section_139.
Mahr A, Heijl C, Le Guenno G. Faurschou M.ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol. 2013;27:45–56.
Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener’s granulomatosis. J Rheumatol. 2008;35:11–3.
Pedersen-Bjergaard J, Specht L, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin’s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987;8550:83–8.
Smith RE. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer. 2003;4:273–9.
Safaa M. Ramadan, Tamer M Fouad, Valentina Summa, Syed KH Hasan, and Francesco Lo-Coco Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica. 2012;97:805–17.
Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52.
Mani D, Dorer RK, Aboulafia DM. Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma. 2009;9:316–9.
Park TS, Cheong JW, Song J, Choi JR. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia. Leuk Res. 2009;33:1001–4.
Bloomfield CD, Archer KJ, Mrózek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:362–78.
Funding
None.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koklu, H., Tufan, A., Erkul, Y. et al. Secondary acute myeloid leukemia arising early after cyclophosphamide treatment. Int J Clin Pharm 37, 289–291 (2015). https://doi.org/10.1007/s11096-015-0069-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-015-0069-4